Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study

Objective. Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease. Methods. Pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2002-06, Vol.85 (3), p.507-510
Hauptverfasser:	Edmonson, John H., Blessing, John A., Cosin, Jonathan A., Miller, David Scott, Cohn, David E., Rotmensch, Jacob
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Cisplatin - administration & dosage Doxorubicin - administration & dosage Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Leiomyosarcoma - drug therapy Medical sciences mitomycin + doxorubicin + cisplatin (MAP) Mitomycin - administration & dosage Pharmacology. Drug treatments Tumors uterine leiomyosarcoma Uterine Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!